Kristine S Alexander1, Neil A Zakai1, Sarah Gillett1, Leslie A McClure1, Virginia Wadley1, Fred Unverzagt1, Mary Cushman2. 1. From the Departments of Medicine (K.S.A., N.A.Z., S.G., M.C.) and Pathology (N.A.Z., M.C.), University of Vermont, Burlington; School of Public Health (L.A.M.) and Division of Gerontology, Geriatrics and Palliative Care, Department of Medicine (V.W.), University of Alabama at Birmingham; and Department of Psychiatry (F.U.), Indiana University School of Medicine, Indianapolis. 2. From the Departments of Medicine (K.S.A., N.A.Z., S.G., M.C.) and Pathology (N.A.Z., M.C.), University of Vermont, Burlington; School of Public Health (L.A.M.) and Division of Gerontology, Geriatrics and Palliative Care, Department of Medicine (V.W.), University of Alabama at Birmingham; and Department of Psychiatry (F.U.), Indiana University School of Medicine, Indianapolis. mary.cushman@uvm.edu.
Abstract
OBJECTIVE: To assess the relationships among ABO group, factor VIII (FVIII), and incident cognitive impairment in a large, prospective cohort study of black and white adults in the United States using a nested case-control design. METHODS: Incident cognitive impairment was defined using cognitive domain tests over a mean follow-up of 3.4 years. ABO blood group was measured by genotyping in a nested case-control sample of 495 cases with cognitive impairment and 587 controls. RESULTS: Those with blood group AB and those with higher FVIII had an increased risk of cognitive impairment, adjusting for age, race, region, and sex (respective odds ratios 1.82, 95% confidence interval [CI] 1.15-2.90; and 1.24, 95% CI 1.10-1.38 for 40 IU/dL higher FVIII). Mean FVIII was higher in those with blood type AB (142 IU/dL; 95% CI 119-165) compared with O (104 IU/dL; 95% CI 101-107), and FVIII mediated 18% of the association between AB group and incident cognitive impairment (95% CI for mediation -30% to 68%). CONCLUSIONS: Blood group AB and higher FVIII were associated with increased incidence of cognitive impairment in this prospective study. The association of blood group AB with incident cognitive impairment was not significantly mediated by FVIII levels.
OBJECTIVE: To assess the relationships among ABO group, factor VIII (FVIII), and incident cognitive impairment in a large, prospective cohort study of black and white adults in the United States using a nested case-control design. METHODS: Incident cognitive impairment was defined using cognitive domain tests over a mean follow-up of 3.4 years. ABO blood group was measured by genotyping in a nested case-control sample of 495 cases with cognitive impairment and 587 controls. RESULTS: Those with blood group AB and those with higher FVIII had an increased risk of cognitive impairment, adjusting for age, race, region, and sex (respective odds ratios 1.82, 95% confidence interval [CI] 1.15-2.90; and 1.24, 95% CI 1.10-1.38 for 40 IU/dL higher FVIII). Mean FVIII was higher in those with blood type AB (142 IU/dL; 95% CI 119-165) compared with O (104 IU/dL; 95% CI 101-107), and FVIII mediated 18% of the association between AB group and incident cognitive impairment (95% CI for mediation -30% to 68%). CONCLUSIONS: Blood group AB and higher FVIII were associated with increased incidence of cognitive impairment in this prospective study. The association of blood group AB with incident cognitive impairment was not significantly mediated by FVIII levels.
Authors: Mary Cushman; Suzanne E Judd; Virginia J Howard; Brett Kissela; Orlando M Gutiérrez; Nancy S Jenny; Ali Ahmed; Evan L Thacker; Neil A Zakai Journal: Stroke Date: 2014-04-22 Impact factor: 7.914
Authors: Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard Journal: Neuroepidemiology Date: 2005-06-29 Impact factor: 3.282
Authors: M Kivipelto; E L Helkala; T Hänninen; M P Laakso; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen Journal: Neurology Date: 2001-06-26 Impact factor: 9.910
Authors: B Winblad; K Palmer; M Kivipelto; V Jelic; L Fratiglioni; L-O Wahlund; A Nordberg; L Bäckman; M Albert; O Almkvist; H Arai; H Basun; K Blennow; M de Leon; C DeCarli; T Erkinjuntti; E Giacobini; C Graff; J Hardy; C Jack; A Jorm; K Ritchie; C van Duijn; P Visser; R C Petersen Journal: J Intern Med Date: 2004-09 Impact factor: 8.989
Authors: T Ohira; M Cushman; M Y Tsai; Y Zhang; S R Heckbert; N A Zakai; W D Rosamond; A R Folsom Journal: J Thromb Haemost Date: 2007-04-09 Impact factor: 5.824
Authors: S R Gillett; L A McClure; P W Callas; E L Thacker; F W Unverzagt; V G Wadley; A J Letter; M Cushman Journal: J Thromb Haemost Date: 2018-06-06 Impact factor: 5.824
Authors: D Leann Long; Boyi Guo; Leslie A McClure; Byron C Jaeger; Stephanie E Tison; George Howard; Suzanne E Judd; Virginia J Howard; Timothy B Plante; Neil A Zakai; Insu Koh; Katharine L Cheung; Mary Cushman Journal: Ann Epidemiol Date: 2021-11-03 Impact factor: 3.797
Authors: Fred Stephen Sarfo; Rufus Akinyemi; George Howard; Virginia J Howard; Kolawole Wahab; Mary Cushman; Deborah A Levine; Adesola Ogunniyi; Fred Unverzagt; Mayowa Owolabi; Bruce Ovbiagele Journal: J Neurol Sci Date: 2020-02-19 Impact factor: 4.553
Authors: Senthil K Vasan; Klaus Rostgaard; Henrik Ullum; Mads Melbye; Henrik Hjalgrim; Gustaf Edgren Journal: PLoS One Date: 2015-06-04 Impact factor: 3.240
Authors: J X Moore; N A Zakai; M Mahalingam; R L Griffin; M R Irvin; M M Safford; J W Baddley; H E Wang Journal: J Thromb Haemost Date: 2016-09-23 Impact factor: 5.824
Authors: Adrienne Tin; Keenan A Walker; Jan Bressler; B Gwen Windham; Michael Griswold; Kevin Sullivan; Aozhou Wu; Rebecca Gottesman; Myriam Fornage; Josef Coresh; A Richey Sharrett; Aaron R Folsom; Thomas H Mosley Journal: Neuroepidemiology Date: 2021-06-02 Impact factor: 5.393